1887

Abstract

Biofilm formation and hemolysis are closely related to the pathogenicity of .

Strategies that reduce the mortality of infections may involve novel antimicrobials and/or drugs that decrease virulence, such as biofilm formation. The antiviral drug efavirenz is a non-nucleoside reverse transcriptase inhibitor, which also has shown antibacterial effect on and . Its effect on pathogen virulence has not yet been explored.

This study investigates the antimicrobial and anti-virulence effect of efavirenz on .

Biofilm biomasses were detected by crystal violet staining. Hemolysis activities of were determined by rabbit erythrocytes lysis assay. RNA levels of transcriptional regulatory genes, biofilm-related genes, and virulence-related genes of were determined by RT-qPCR.

Efavirenz showed an inhibitory effect on the growth of , and at 50 µM. Efavirenz significantly inhibited biofilm formation of both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) at 25 µM, but did not affect the growth of planktonic cells. Moreover, hemolysis by was inhibited by efavirenz at 25 µM. The expression levels of RNA transcriptional regulatory genes (, , , and ), biofilm-related genes (, , , , ), and virulence-related genes (, , , , ) of decreased significantly at 25 µM efavirenz.

Efavirenz inhibits biofilm formation and virulence .

Funding
This study was supported by the:
  • National Natural Science Foundation of China (Award 81902033)
    • Principle Award Recipient: YongpengShang
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001433
2021-10-20
2024-06-20
Loading full text...

Full text loading...

References

  1. David MZ, Daum RS. Treatment of Staphylococcus aureus infections. Curr Top Microbiol Immunol 2017; 409:325–383 [View Article] [PubMed]
    [Google Scholar]
  2. Lakhundi S, Zhang K. Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology. Clin Microbiol Rev 2018; 31:e00020-18 [View Article] [PubMed]
    [Google Scholar]
  3. Diaz R, Afreixo V, Ramalheira E, Rodrigues C, Gago B. Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections-a systematic review and meta-analysis. Clin Microbiol Infect 2018; 24:97–104 [PubMed]
    [Google Scholar]
  4. Shariati A, Dadashi M, Chegini Z, van Belkum A, Mirzaii M. The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis. Antimicrob Resist Infect Control 2020; 9:56 [View Article] [PubMed]
    [Google Scholar]
  5. McEwen SA, Collignon PJ. Antimicrobial resistance: a one health perspective. Microbiol Spectr 2018; 6: [View Article] [PubMed]
    [Google Scholar]
  6. Maura D, Ballok AE, Rahme LG. Considerations and caveats in anti-virulence drug development. Curr Opin Microbiol 2016; 33:41–46 DOI:10.1016/j.mib.2016.06.001 [PubMed]
    [Google Scholar]
  7. Moormeier DE, Bayles KW. Staphylococcus aureus biofilm: a complex developmental organism. Mol Microbiol 2017; 104:365–376 [View Article] [PubMed]
    [Google Scholar]
  8. Suresh MK, Biswas R, Biswas L. An update on recent developments in the prevention and treatment of Staphylococcus aureus biofilms. Int J Med Microbiol 2019; 309:1–12 DOI: 10.1016/j.ijmm.2018.11.002 [PubMed]
    [Google Scholar]
  9. Otto M. Staphylococcal Biofilms. Microbiol Spectr 2018; 6: [View Article] [PubMed]
    [Google Scholar]
  10. Lee K, Lee JH, Kim SI, Cho MH, Lee J. Anti-biofilm, anti-hemolysis, and anti-virulence activities of black pepper, cananga, myrrh oils, and nerolidol against Staphylococcus aureus . Appl Microbiol Biotechnol 2014; 98:9447–9457 [View Article] [PubMed]
    [Google Scholar]
  11. Kryst J, Kawalec P, Pilc A. Efavirenz-based regimens in antiretroviral-naive hiv-infected patients: a systematic review and meta-analysis of randomized controlled trials. PloS one 2015; 10:e0124279 [View Article] [PubMed]
    [Google Scholar]
  12. Shilaih M, Angst DC, Marzel A, Bonhoeffer S, Günthard HF et al. Antibacterial effects of antiretrovirals, potential implications for microbiome studies in HIV. AntivirTher 2018; 23:91–94
    [Google Scholar]
  13. Sun X, Lin ZW, Hu XX, Yao WM, Bai B. Biofilm formation in erythromycin-resistant Staphylococcus aureus and the relationship with antimicrobial susceptibility and molecular characteristics. Microb Pathog 2018; 124:47–53 [PubMed]
    [Google Scholar]
  14. Freer JH, Arbuthnott JP, Bernheimer AW. Interaction of staphylococcal alpha-toxin with artificial and natural membranes. J Bacteriol 1968; 95:1153–1168 [View Article] [PubMed]
    [Google Scholar]
  15. Shang Y, Wang X, Chen Z, Lyu Z, Lin Z. Staphylococcus aureus PhoU homologs regulate persister formation and virulence. Front Microbiol 2020; 11:865 [View Article] [PubMed]
    [Google Scholar]
  16. Zheng JX, Tu P, Sun X, Xu GJ, Chen JW. In vitro activities of telithromycin against Staphylococcus aureus biofilms compared with azithromycin, clindamycin, vancomycin and daptomycin. J Med Microbiol 2020; 69:120–131 [View Article] [PubMed]
    [Google Scholar]
  17. Zheng J, Shang Y, Wu Y, Wu J, Chen J. Diclazuril inhibits biofilm formation and hemolysis of Staphylococcus aureus . ACS Infect Dis 2021; 7:1690–1701 [View Article] [PubMed]
    [Google Scholar]
  18. Seidl K, Goerke C, Wolz C, Mack D, Berger-Bächi B. Staphylococcus aureus CcpA affects biofilm formation. Infect Immun 2008; 76:2044–2050 [View Article] [PubMed]
    [Google Scholar]
  19. Herbert S, Ziebandt AK, Ohlsen K, Schäfer T, Hecker M. Repair of global regulators in Staphylococcus aureus 8325 and comparative analysis with other clinical isolates. Infect Immun 2010; 78:2877–2889 [View Article] [PubMed]
    [Google Scholar]
  20. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother 2009; 64:910–928 [View Article] [PubMed]
    [Google Scholar]
  21. Baldry M, Nielsen A, Bojer MS, Zhao Y, Friberg C. Norlichexanthone reduces virulence gene expression and biofilm formation in Staphylococcus aureus . PloS one 2016; 11:e0168305 [View Article] [PubMed]
    [Google Scholar]
  22. Lee JH, Kim YG, Yong Ryu S, Lee J. Calcium-chelating alizarin and other anthraquinones inhibit biofilm formation and the hemolytic activity of Staphylococcus aureus . Sci Rep 2016; 6:19267 [View Article] [PubMed]
    [Google Scholar]
  23. Kong C, Chee CF, Richter K, Thomas N, AbdRahman N. Suppression of Staphylococcus aureus biofilm formation and virulence by a benzimidazole derivative, UM-C162. Sci Rep 2018; 8:2758 [View Article] [PubMed]
    [Google Scholar]
  24. Song L, Hobaugh MR, Shustak C, Cheley S, Bayley H. Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore. Science 1996; 274:1859–1866 [View Article] [PubMed]
    [Google Scholar]
  25. Guillet V, Roblin P, Werner S, Coraiola M, Menestrina G. Crystal structure of leucotoxin S component: new insight into the Staphylococcal beta-barrel pore-forming toxins. J Biol Chem 2004; 279:41028–41037 [View Article] [PubMed]
    [Google Scholar]
  26. Vandenesch F, Lina G, Henry T. Staphylococcus aureus hemolysins, bi-component leukocidins, and cytolytic peptides: a redundant arsenal of membrane-damaging virulence factors?. Front Cell Infect Microbiol 2012; 2:12 [View Article] [PubMed]
    [Google Scholar]
  27. Sonnen AF, Henneke P. Role of pore-forming toxins in neonatal sepsis. Clin Dev Immunol 2013; 2013:608456 [View Article] [PubMed]
    [Google Scholar]
  28. Sinxadi PZ, McIlleron HM, Dave JA, Smith PJ, Levitt NS. Plasma Efavirenz concentrations are associated with lipid and glucose concentrations. Medicine (Baltimore) 2016; 95:e2385 [View Article] [PubMed]
    [Google Scholar]
  29. Oliveira WF, Silva PMS, Silva RCS, Silva GMM, Machado G. Staphylococcus aureus and Staphylococcus epidermidis infections on implants. J Hosp Infect 2018; 98:111–117 [View Article] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001433
Loading
/content/journal/jmm/10.1099/jmm.0.001433
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error